Summit Therapeutics (SMMT) EPS (Weighted Average and Diluted) (2017 - 2025)
Historic EPS (Weighted Average and Diluted) for Summit Therapeutics (SMMT) over the last 5 years, with Q3 2025 value amounting to -$0.31.
- Summit Therapeutics' EPS (Weighted Average and Diluted) fell 28750.0% to -$0.31 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.25, marking a year-over-year decrease of 42083.33%. This contributed to the annual value of -$0.33 for FY2024, which is 6700.89% up from last year.
- Per Summit Therapeutics' latest filing, its EPS (Weighted Average and Diluted) stood at -$0.31 for Q3 2025, which was down 28750.0% from -$0.76 recorded in Q2 2025.
- Summit Therapeutics' EPS (Weighted Average and Diluted)'s 5-year high stood at -$0.01 during Q4 2023, with a 5-year trough of -$0.76 in Q2 2025.
- In the last 4 years, Summit Therapeutics' EPS (Weighted Average and Diluted) had a median value of -$0.09 in 2024 and averaged -$0.15.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first surged by 7500.0% in 2023, then plummeted by 81328.01% in 2024.
- Summit Therapeutics' EPS (Weighted Average and Diluted) (Quarter) stood at -$0.04 in 2022, then skyrocketed by 75.0% to -$0.01 in 2023, then crashed by 813.28% to -$0.09 in 2024, then tumbled by 239.44% to -$0.31 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.31 for Q3 2025, versus -$0.76 for Q2 2025 and -$0.09 for Q1 2025.